|1.||Li, Xiuling: 4 articles (08/2014 - 11/2007)|
|2.||Tai, Hsin-Hsiung: 4 articles (08/2014 - 11/2007)|
|3.||Wei, Jingyan: 2 articles (07/2010 - 11/2007)|
|4.||Yokoyama, Utako: 1 article (01/2014)|
|5.||Iwai, Kenji: 1 article (01/2014)|
|6.||Liu, Norika Mengchia: 1 article (01/2014)|
|7.||Shiraishi, Ryosuke: 1 article (01/2014)|
|8.||Minamisawa, Susumu: 1 article (01/2014)|
|9.||Aida, Takashi: 1 article (01/2014)|
|10.||Yokota, Tomohiro: 1 article (01/2014)|
|1.||Lung Neoplasms (Lung Cancer)
09/01/2009 - "We report here that the activation of TP by its agonist, [1S-[1alpha, 2alpha (Z), 3beta (1E, 3S*), 4alpha]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo [2.2.1] hept-2-yl]-5-heptenoic acid (I-BOP), induced Nurr1 expression and stimulated proliferation of human lung cancer cells. "
11/01/2007 - "Both 12-HHT- and I-BOP-induced activations of ERKs were also examined in other human prostate cancer cells, human lung cancer cells, and human lung fibroblast. "
08/01/2014 - "Earlier it was reported that I-BOP-initiated activation of thromboxane A2 receptor (TP) induced the release of MMP-1, MMP-3, and MMP-9 from lung cancer A549 cells overexpressing TPα (A549-TPα). "
07/01/2010 - "I-BOP, an agonist of TP, stimulated the expression of VEGF in this cell line as well as in another human lung cancer H157 cells in a time and dose dependent manner. "
|4.||Prostatic Neoplasms (Prostate Cancer)
|5.||Nephrotic Syndrome (Syndrome, Nephrotic)
|1.||15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
|2.||Prostaglandin H2 (PGH(2))
|3.||Prostaglandin H2 Thromboxane A2 Receptors
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)